Superpower peptides available for pre-order. Get first access.

Peptide science

Is VK2735 FDA-approved?

VK2735 is not FDA-approved. See where its Phase 3 VANQUISH and SUNRISE trials stand, what must happen before approval, and whether anyone can get it now.

Quick answer

VK2735 is not FDA-approved for any use. It is an investigational drug in Phase 3 trials. Its once-weekly injection trials, VANQUISH-1 (about 4,500 adults) and VANQUISH-2 (about 1,000), last 78 weeks and are expected to complete in 2027, per Viking Therapeutics. Viking has also initiated SUNRISE-1 and SUNRISE-2, once-daily tablet trials each targeting 560 adults. A New Drug Application and FDA review come next, so no approval date exists.

Published
November 10, 2026
Last updated
November 10, 2026

VK2735 FDA approval status in November 2026

VK2735 is an investigational drug in Phase 3 trials and is not FDA-approved for any use1. Viking Therapeutics expects its Phase 3 trials of the once-weekly injection to be completed in 20272. Until FDA has reviewed what those trials show, no one can put a date on VK2735 FDA approval.

VK2735 Phase 3 trials cover the injection and the tablet

VK2735 is in two Phase 3 programs, one testing a weekly injection and the other a daily tablet. Viking's VANQUISH program gives the injection under the skin once a week for 78 weeks2. The SUNRISE program tests the tablet once a day for 68 weeks3.

Both programs measure percent change in body weight4. Each one runs a trial in adults without type 2 diabetes and a second in adults with type 2 diabetes5.

Both VK2735 forms reached Phase 3 through Phase 2 trials: the 13-week VENTURE injection trial6 and the VENTURE-Oral tablet trial of 280 adults7.

Viking's enrollment figures for VK2735's Phase 3 trials and the registry's estimates differ only for VANQUISH-2.

TrialForm and doses testedPopulationPlanned dosing periodEnrollmentStatusExpected completion
VANQUISH-14Once-weekly injection, 7.5, 12.5, or 17.5 mg, or placeboAdults with obesity, or overweight plus a weight-related condition, without type 2 diabetes78 weeksAbout 4,500 enrolled (Viking)2; 4,500 estimated (registry)Active, not recruitingCompletion expected in 2027 (Viking)2; primary completion estimated July 2027 (registry)
VANQUISH-28Once-weekly injection, 7.5, 12.5, or 17.5 mg, or placeboAdults with obesity or overweight and type 2 diabetes78 weeksAbout 1,000 enrolled (Viking)2; 1,100 estimated (registry)Active, not recruitingCompletion expected in 2027 (Viking)2; primary completion estimated July 2027 (registry)
SUNRISE-13Once-daily tablet, 27.5, 35, or 55 mg2, or placeboAdults with obesity, or overweight plus a weight-related condition, without type 2 diabetes68 weeks560 adults targetedInitiated (Viking)2; not yet recruiting (registry)Primary completion estimated July 2028 (registry)
SUNRISE-29Once-daily tablet, 27.5, 35, or 55 mg2, or placeboAdults with obesity or overweight and type 2 diabetes68 weeks560 adults targetedInitiated (Viking)2; not yet recruiting (registry)Primary completion estimated October 2028 (registry)
VANQUISH extension studiesOnce-weekly injectionNot statedUp to 52 more weeks (Viking)2Not statedExpected to start in first quarter of 20272 (Viking)Extension results expected in 2028 (Viking)

The VANQUISH results, once reported, start the regulatory path that ends in an FDA decision on VK2735.

VK2735 needs three more steps before FDA approval

VK2735 has three sequential steps left before FDA can decide on approval10.

  1. Phase 3 results: Phase 3 trials, often called pivotal studies, show whether a drug offers a treatment benefit11 and supply most of its safety data. Metabolic drugs that reach Phase 3 do not always go on to approval12.
  2. A New Drug Application: Viking would then file a New Drug Application, the formal request for FDA approval for sale13. That application gathers everything from early research to Phase 3 results10.
  3. FDA review: Once FDA accepts the application as complete, its review team has 6 to 10 months to decide10. FDA's goal for acting on an application is six months under priority review, 10 under standard14. From 2012 to 2022, the median review for new drugs ran just under 10 months15.

Until all three steps are done, VK2735 stays investigational and out of general use.

VK2735 access is limited to clinical trials

VK2735 reaches people through enrollment in its clinical trials. Federal law lets an investigational new drug ship across state lines only to clinical investigators16.

No doctor can write a standard prescription for VK2735, and no pharmacy can sell it over the counter. Every new drug needs an approved New Drug Application before US sale13.

Pharmacies cannot compound VK2735 either, because federal compounding rules limit which bulk substances they may use. A bulk substance qualifies with an official USP or NF quality standard17, a role in an FDA-approved drug, or a place on the 503A bulks list18. VK2735 meets none of those conditions. VK2735 is also absent from the HHS peptide compounding policy of October 30, 202619, which covers six other peptides20.

Products sold online as VK2735 outside a trial are not FDA-approved drugs. Unapproved GLP-1 (glucagon-like peptide-1) drugs sold with a "for research purposes" label are of unknown quality and may be harmful21. Online searches for semaglutide surface many illegal pharmacy operations22. Test purchases from such sellers turned up probable falsified or substandard vials23.

Expanded access, or compassionate use, is a narrow FDA exception, not a standard route, and is limited to serious or immediately life-threatening conditions1. That pathway also requires that no comparable alternative exists and that trial enrollment is not possible. No VK2735 record on ClinicalTrials.gov lists an expanded-access program24. ClinicalTrials.gov lists each VK2735 trial's purpose, who may participate, locations, and phone numbers25. Unlike VK2735, FDA-approved versions21 of some GLP-1 receptor agonists are already on the market.

Where can I learn about peptides?

Superpower’s peptide library explains investigational drugs like VK2735 and where each stands in testing. A team of health journalists and licensed clinicians writes and fact-checks every guide.

The library's guides to the science behind peptides explain how peptide drugs are built and tested.

IMPORTANT SAFETY INFORMATION

VK2735 is an investigational drug in clinical development by Viking Therapeutics. It has not been approved by the FDA for any medical use, and no FDA approval date exists. VK2735 meets none of the federal conditions for a bulk substance used in compounding and is not named in the HHS peptide compounding policy of October 30, 2026, so it is not lawfully available through compounding pharmacies in the United States. This page is provided for educational purposes only and does not constitute medical advice.

VK2735 reaches people through enrollment in its clinical trials. Products sold online as VK2735 outside a trial are not FDA-approved drugs, and FDA states that unapproved GLP-1 drugs sold with a "for research purposes" label are of unknown quality and may be harmful.

No FDA-approved prescribing information exists for VK2735. For registered clinical trial information, see ClinicalTrials.gov24.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to VK2735. VK2735 is an investigational compound that is not FDA-approved; access is limited to clinical trial enrollment. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science